Drug Target Discovery in Mycobacterium Tuberculosis

Drug target discovery in Mycobacterium tuberculosis has evolved from individual enzyme inhibition to systems-level analyses that integrate genomic, proteomic and biochemical data. Efforts seek to identify essential bacterial functions that, when disrupted, curtail growth or persistence in host tissues. Classical approaches have focused on cell wall biosynthesis, energy metabolism and cofactor production, while contemporary strategies employ subtractive proteomics, pangenomic comparisons and high-throughput screening to reveal broad-spectrum vulnerabilities. The global rise of multidrug-resistant and extensively drug-resistant strains has intensified the search for novel targets, including those involved in coenzyme A biosynthesis, lipid virulence factor assembly and nucleotide metabolism. By combining in silico docking, molecular dynamics simulation and experimental validation, researchers aim to accelerate the development of compounds with potent activity against both replicating and persistent bacilli, thereby shortening treatment regimens and overcoming resistance.

Research from Nature Portfolio

Recent studies have used large-scale comparative genomics to map the core proteome of M. tuberculosis, applying sequential filters for non-human homology, essentiality and virulence to pinpoint high-confidence targets. Identified proteins were subjected to molecular docking with existing drug libraries, yielding candidate inhibitors that showed stable binding and favourable dynamics in silico, setting the stage for experimental lead optimisation. In parallel, the structure of the bifunctional CoaBC enzyme involved in coenzyme A biosynthesis has been solved at atomic resolution, revealing a cryptic allosteric pocket. Biochemical screening uncovered small-molecule scaffolds that selectively bind this site and inhibit enzyme function, demonstrating bactericidal effects and offering a blueprint for allosteric inhibitor design against an otherwise elusive enzyme.

Drug Target Discovery in Mycobacterium Tuberculosis publication trend

The graph below shows the total number of articles in drug target discovery in mycobacterium tuberculosis across all publications each year (not limited to Nature Index journals).

Technical terms

Pangenome: The full complement of genes across multiple strains of a species, comprising core and accessory genomes.

Molecular docking: A computational method that predicts the preferred orientation and binding energy of a ligand within a target protein’s active or allosteric site.

Molecular dynamics simulation: A computer-based technique to model the time-dependent behaviour of molecular systems at atomic resolution.

Allosteric site: A region of an enzyme distinct from the active site where ligand binding regulates catalytic activity.

Pantothenate synthetase: An enzyme that catalyses the condensation of pantoate and β-alanine to form pantothenate, a precursor of coenzyme A.

Phosphopantetheinyl transferase (PPTase): An enzyme that activates carrier proteins by transferring a 4′-phosphopantetheine moiety from coenzyme A, essential for fatty acid and polyketide synthesis in mycobacteria.

References

1. Mycobacterium tuberculosis: Pathogenesis and therapeutic targets. MedComm (2023).
2. Exploring optimal drug targets through subtractive proteomics analysis and pangenomic insights for tailored drug design in tuberculosis. Scientific Reports (2024).
3. Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site. Nature Communications (2021).
4. Unearthing phytochemicals as natural inhibitors for pantothenate synthetase in Mycobacterium tuberculosis: A computational approach. Frontiers in Pharmacology (2024).
5. Exploring Indonesian actinomycete extracts for anti-tubercular compounds: Integrating inhibition assessment, genomic analysis, and prediction of its target by molecular docking. Heliyon (2024).
6. The quest for the holy grail: new antitubercular chemical entities, targets and strategies. Drug Discovery Today (2020).